Company intelligence / Profile preview

Pediatrix Therapeutics

Shanghai, Shanghai, Chinapediatrixtherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Pediatrix has successfully conducted bridging PK/PD studies of neffy® intranasal epinephrine in Chinese patients that replicated U.S. results. The company is actively developing ATI‑1777 ("soft" JAK inhibitor) for dermatological conditions under a license from Aclaris. It is also expanding its pipeline through partnerships such as with Tris Pharma for ADHD therapies.

Therapeutic areas: PsychiatryImmunology
Modalities: Small molecules (e.g., JAK inhibitors)Intranasal formulations (e.g., epinephrine nasal spray)Pediatric-friendly drug formulations
Industry: Biotech

Drug pipeline

1 asset

ATI-1777

Phase 1

Indications: Atopic dermatitis

Partnerships

ARS Pharmaceuticals – exclusive partner/distributor of neffy® in China/Japan/Australia/NZ.Aclaris Therapeutics – exclusive licensee of ATI‑1777 for Greater China.Tris Pharma – commercializing ADHD portfolio/pipeline products in China.

Beyond the preview

Go deeper on Pediatrix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pediatrix Therapeutics.